Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience

BACKGROUND: Certolizumab pegol (CZP) has been successfully used for the treatment of Crohn disease (CD); however, real-world data regarding the utility of CZP trough levels (CTLs) are lacking. We aimed to correlate CTL with CD outcomes and to determine frequency of CZP antibodies. METHODS: Retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos, Guilherme Piovezani, Al-Bawardy, Badr, Braga Neto, Manuel Bonfim, Bledsoe, Adam C, Quinn, Kevin P, Heron, Valérie, Willrich, Maria Alice V, Johnson, Amanda, Chedid, Victor G, Coelho-Prabhu, Nayantara, Kisiel, John B, Papadakis, Konstantinos A, Pardi, Darrell, Kane, Sunanda, Tremaine, William J, Raffals, Laura, Bruining, David H, Faubion, William A, Harmsen, William S, Loftus, Edward V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802288/
https://www.ncbi.nlm.nih.gov/pubmed/36776673
http://dx.doi.org/10.1093/crocol/otab019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802288/
https://www.ncbi.nlm.nih.gov/pubmed/36776673
http://dx.doi.org/10.1093/crocol/otab019

Ejemplares similares